Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
Open Access
- 17 January 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 225
Abstract
Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes. Its mortality rate accounts for 90% of all dermatologic tumor mortality. Traditional treatments such as surgery, chemotherapy, and radiotherapy are unable to achieve the expected results due to MM’s low sensitivity, high drug resistance, and toxic side effects. As treatment advances, immunotherapy and targeted therapy have made significant breakthroughs in the treatment of MM and have demonstrated promising application prospects. However, the heterogeneity of tumor immune response causes more than half of patients to not benefit from clinical immunotherapy and targeted therapy, which delays the patient’s condition and causes them to suffer adverse immune events’ side effects. The combination of immunotherapy and targeted therapy can help improve therapeutic effects, delay drug resistance, and mitigate adverse effects. This review provides a comprehensive overview of the current development status and research progress of immune checkpoints, targeted genes, and their inhibitors, with a view to providing a reference for the clinical treatment of MM.Keywords
Funding Information
- National Natural Science Foundation of China (32070395, 82103055, 242102311166)
- Key Science and Technology Research Project of Henan Province of China (32070395, 82103055, 242102311166)
This publication has 116 references indexed in Scilit:
- Factors associated with skeletal‐related events in patients with bone metastatic melanoma: A retrospective study of 481 patientsJournal of Surgical Oncology, 2024
- Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017Journal of Cancer Research and Clinical Oncology, 2024
- Mechanisms of Resistance to Checkpoint Blockade Therapy2020
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumabCancer Medicine, 2019
- Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanomaClinical and Translational Oncology, 2019
- Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursInvestigational New Drugs, 2019
- Immune Checkpoint Inhibitors-Induced Hepatitis2018
- PD‐1 as a potential target in cancer therapyCancer Medicine, 2013
- Targeted therapy for oesophageal cancer: an overviewCancer and Metastasis Reviews, 2008
- Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapyInternational Journal of Cancer, 2005